コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 genome (e.g., by irradiation or radiomimetic chemotherapeutics).
2 patient samples (16 untreated, 3 treated by chemotherapeutics).
3 luding both targeted as well as conventional chemotherapeutics.
4 w bacteria affect the C. elegans response to chemotherapeutics.
5 S-driven cancers are infamously resistant to chemotherapeutics.
6 res in response to metabolic inhibitors, and chemotherapeutics.
7 pecific effects regulating the resistance to chemotherapeutics.
8 e rational design of alpha-tubulin targeting chemotherapeutics.
9 tance (MDR), being capable of effluxing many chemotherapeutics.
10 astasis and to increase tumor sensitivity to chemotherapeutics.
11 f unique molecules including highly valuable chemotherapeutics.
12 meter-sized particle that can be loaded with chemotherapeutics.
13 nge of clinical and preclinical stage cancer chemotherapeutics.
14 increases tumour sensitivity to conventional chemotherapeutics.
15 nd following treatment with mitosis-blocking chemotherapeutics.
16 tment to improve the efficacy of traditional chemotherapeutics.
17 potential adjuvants for DNA-damaging cancer chemotherapeutics.
18 ions and metabolites to siRNA, peptides, and chemotherapeutics.
19 e strategy for the development of anticancer chemotherapeutics.
20 apoptosis in breast cancer cells exposed to chemotherapeutics.
21 logy research tools and clinically as cancer chemotherapeutics.
22 signaling and open the door to new selective chemotherapeutics.
23 rs can enhance the efficacy of common cancer chemotherapeutics.
24 pt host-parasite interactions, or to deliver chemotherapeutics.
25 so the cellular target of camptothecin (CPT) chemotherapeutics.
26 eration and a target of commonly used cancer chemotherapeutics.
27 isease progression and resistance to current chemotherapeutics.
28 anslates into an enhanced ability to deliver chemotherapeutics.
29 epresent candidate molecular targets for new chemotherapeutics.
30 sistant to a variety of chemically unrelated chemotherapeutics.
31 ity and are garnering increasing interest as chemotherapeutics.
32 ide range of imidazole-based antibiotics and chemotherapeutics.
33 methyltransferases (KMTs) being developed as chemotherapeutics.
34 and are resistant to conventional cytotoxic chemotherapeutics.
35 as well as an increasing variety of anionic chemotherapeutics.
36 -based antiretroviral medications and cancer chemotherapeutics.
37 the delivery of HSP targeted macromolecular chemotherapeutics.
38 y and repopulate the tumor after exposure to chemotherapeutics.
39 er, immunosuppressant, and anti-inflammatory chemotherapeutics.
40 breast cancers, which are resistant to many chemotherapeutics.
41 vances and the development of more effective chemotherapeutics.
42 umor penetration and therapeutic efficacy of chemotherapeutics.
43 ionizing radiation as well as treatment with chemotherapeutics.
44 cers, as well as resistance to commonly used chemotherapeutics.
45 tumors while minimizing systemic exposure to chemotherapeutics.
46 harnessed extensively as carriers for cancer chemotherapeutics.
47 ptosis and enhances the potency of cytotoxic chemotherapeutics.
48 allows cell survival, even against cytotoxic chemotherapeutics.
49 CITED2), a gene that mediates sensitivity to chemotherapeutics.
50 the tumor, is also resistant to conventional chemotherapeutics.
51 reme resistance to conventional DNA-damaging chemotherapeutics.
52 overcoming major drawbacks of currently used chemotherapeutics.
53 esidues associated with resistance to cancer chemotherapeutics.
54 and bound to the three structurally distinct chemotherapeutics.
55 hat they have emerged as excellent potential chemotherapeutics.
56 ion of IL-8 pathway to the class of platinum chemotherapeutics.
57 in tumor, can evaluate the effectiveness of chemotherapeutics.
58 ia in order to increase the effectiveness of chemotherapeutics.
59 ntifolates that could potentially be used as chemotherapeutics.
60 s can potentially improve the selectivity of chemotherapeutics.
61 eric radiation, environmental chemicals, and chemotherapeutics.
62 ies and DNA-damaging agents that are used as chemotherapeutics.
63 latinum drugs, which are among the most used chemotherapeutics.
64 sistance and rapidly identifying combination chemotherapeutics.
65 ICD can be induced by treatment with chemotherapeutics.
66 es the anticancer efficacy of platinum-based chemotherapeutics.
67 ng TLS is an attractive avenue for improving chemotherapeutics.
68 e panel of DNA-damaging agents, enriched for chemotherapeutics.
69 the role of bacteria in the host response to chemotherapeutics.
70 l line exacerbated DNA damage in response to chemotherapeutics.
71 ncer that resists efforts to identify better chemotherapeutics.
72 e-of-day may alter inflammatory responses to chemotherapeutics.
73 atory axis, conferring resistance to various chemotherapeutics.
74 resistance to a broad range of DNA-damaging chemotherapeutics.
75 tin, are some of the most widely used cancer chemotherapeutics.
76 ent blood-brain barrier (BBB) penetration of chemotherapeutics.
77 revealing a broad window for PfCRK4-targeted chemotherapeutics.
81 poor and nonselective penetration of current chemotherapeutics across the plasma membranes of cancer
83 potential mechanism by which p53-activating chemotherapeutics, acting upon p53-sufficient macrophage
84 , F. evanescens, and U. pinnatifida as novel chemotherapeutics against different types of cancer.
88 DE cultures were exposed to standard-of-care chemotherapeutics agents for 2 weeks, attesting the abil
90 e encapsulating ATP-responsive elements with chemotherapeutics and a liposome containing ATP was deve
92 apies, including multiple chemotherapeutics, chemotherapeutics and biologics, chemotherapeutics and p
94 ologically inhibit GATA2 in concert with AML chemotherapeutics and found this augmented cell killing
95 /AEG-1 mice displayed profound resistance to chemotherapeutics and growth factor deprivation with act
96 ess the spatial distribution of administered chemotherapeutics and metabolites with MALDI-imaging mas
97 le disease, but the combination of optimized chemotherapeutics and molecularly targeted agents holds
98 c cancer cell lines with clinically relevant chemotherapeutics and monitored proteolytic fragments re
99 concerning the sensitivity towards different chemotherapeutics and moreover, can obtain resistance, t
100 erapeutics, chemotherapeutics and biologics, chemotherapeutics and photodynamic therapy, and chemothe
101 associated with resistance to platinum-based chemotherapeutics and poly(ADP ribose) polymerase (PARP)
102 ns with standard-of-care treatments (such as chemotherapeutics and radiation), novel molecularly targ
104 on, increase accessibility for DNA targeting chemotherapeutics and reduce cytotoxic drug resistance.N
106 izes KRAS-mutated leukemic cells to standard chemotherapeutics and represents a promising approach fo
107 cancer stem cells (CSCs), more resistant to chemotherapeutics and responsible of GBM recurrence; (iv
108 e platform vehicle that can encapsulate both chemotherapeutics and siRNA to achieve maximal efficacy
109 n and survival in response to UVB stress and chemotherapeutics and suggest that Sesn2 is oncogenic in
111 emically modified liposomes for loading with chemotherapeutics and targeting them for the transporter
112 ancer specificity of prodrugs from classical chemotherapeutics and the potency of mitotic kinase inhi
113 opulation of supportive BMDCs in response to chemotherapeutics and uncovered a new potential strategy
114 treated with rituximab, 34.5% with different chemotherapeutics, and 13.8% with corticosteroids only f
115 lonal antibodies, small molecule inhibitors, chemotherapeutics, and cell-based treatment strategies h
116 induced by environmental methylating agents, chemotherapeutics, and natural cellular methyl donors.
117 45 muM), the standard metallodrug used in CC chemotherapeutics, and our leading compound 14Ru was sho
118 CLs) are generated by endogenous sources and chemotherapeutics, and pose a threat to genome stability
119 responding to the threat; new knowledge and chemotherapeutics are being created to safeguard our fut
121 ny human diseases, including cancer, wherein chemotherapeutics are exported from target cells by memb
126 inhibitors of sirtuins for potential use as chemotherapeutics as well as tools to modulate sirtuin a
127 A lesions caused by reactive metabolites and chemotherapeutics, as well as stable nucleoprotein compl
128 argeted herein for the controlled release of chemotherapeutics at the tumour site, while sparing heal
130 used for development of novel DNA-targeting chemotherapeutics based on benzo[c]quinolizinium derivat
131 stemic toxicities associated with modern day chemotherapeutics but also address resistance issues tha
132 TCF3-HLF ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids, an
133 Other options include observation or novel chemotherapeutics, but little guidance exists on selecti
134 er cells to PARP inhibitors and DNA-damaging chemotherapeutics by reducing expression of the genes in
135 cells, combining immunotherapy with certain chemotherapeutics can lead to increased efficacy compare
137 Acute treatment with replication-stalling chemotherapeutics causes reversal of replication forks.
138 of combination therapies, including multiple chemotherapeutics, chemotherapeutics and biologics, chem
140 These NCP particles contain high payloads of chemotherapeutics cisplatin or cisplatin plus gemcitabin
141 presence of nontargeted chemicals including chemotherapeutics consistent with a local hospital waste
142 CAR inhibitors, in combination with existing chemotherapeutics, could therefore be used to attenuate
144 c options that moves away from the expensive chemotherapeutics currently dominating the research clim
146 l compound camptothecin (CPT) and the cancer chemotherapeutics derived from it, irinotecan and topote
148 Interestingly, radiation and antimitotic chemotherapeutics did not increase overall tumor burden
150 The change in impedance magnitude on flowing chemotherapeutics drugs measured at 12h for drug-suscept
152 drug resistance via lysosomes, the cytotoxic chemotherapeutics (e.g. DOX, daunorubicin, or vinblastin
155 he SK1-specific inhibitor SK1-I and standard chemotherapeutics, expression of CIB2 also sensitized ov
158 stent with these observations, IFN-gamma and chemotherapeutics failed to activate autophagy in CLL pa
159 re are five clinically approved nanoparticle chemotherapeutics for cancer and many more under clinica
161 xifen and fulvestrant have been evaluated as chemotherapeutics for ovarian cancer, particularly in ca
162 ynamic abilities of porphyrinoids, can carry chemotherapeutics for synergistic modalities, and can be
164 model, with values similar to currently used chemotherapeutics for the treatment of solid tumors.
169 administration of UPI peptide with cytotoxic chemotherapeutics further sustained tumor inhibition.
175 s and resistances of kinases to DNA-damaging chemotherapeutics have not been possible, partially due
177 Despite the broad use of platinum-based chemotherapeutics, identification of their full range of
178 t potent additivity or synergy with existing chemotherapeutics in animal models of cancer and may red
182 B, and Janus kinase, which are activated by chemotherapeutics in epithelial cell-transitioned prosta
183 and reduced sensitivity to antiestrogens and chemotherapeutics in estrogen receptor alpha (ERalpha)-p
186 he immunostimulatory effects of conventional chemotherapeutics in the context of ICI-based immunother
188 in development in rats caused by widely used chemotherapeutics in the taxane (paclitaxel), platinum-c
192 single agents and in combination with other chemotherapeutics, in several subtypes of breast cancer
193 shed targets of some of the most widely used chemotherapeutics, including dihydrofolate reductase, th
194 s induced synthetic lethality with genotoxic chemotherapeutics, including PARP inhibitors, and nongen
195 In response to the challenges of cancer chemotherapeutics, including poor physicochemical proper
196 protection against the cytotoxic actions of chemotherapeutics, including reductions in oxidative str
198 tically, we observe that mTOR inhibitors and chemotherapeutics induce translational activation of a s
199 cytes mediate the resistance to DNA-damaging chemotherapeutics induced by two platinum-induced fatty
200 sm constitutes a rich source of antibiotics, chemotherapeutics, insecticides and other high-value che
202 a induced by inflammation, nerve injury, and chemotherapeutics is abolished in mice lacking the neuro
206 e clinical use of multiple classes of cancer chemotherapeutics is limited by irreversible, dose-depen
207 r challenge in the clinical use of cytotoxic chemotherapeutics is maximizing efficacy in tumors while
208 fective and safer treatments, especially non-chemotherapeutics, is needed for patients with Waldenstr
209 here Pgp-mediated lysosomal sequestration of chemotherapeutics leads to MDR that is amenable to thera
214 ations, including the mitochondria-targeting chemotherapeutics lonidamine and alpha-tocopheryl succin
216 is considered a crucial target for platinum chemotherapeutics, metallodrug-DNA binding studies domin
217 (CLL) involve a combination of conventional chemotherapeutics, monoclonal antibodies, and targeted s
221 e storm or through direct effects of certain chemotherapeutics on stromal and/or immune cells, the mo
222 Combination therapy can include multiple chemotherapeutics or combinations of chemotherapeutics w
223 plementary immunotherapeutic strategies with chemotherapeutics or other oncogenic pathway inhibitors.
226 r-1 (NCP-1) for simultaneous delivery of two chemotherapeutics, oxaliplatin and gemcitabine monophosp
227 rs for encapsulating 17-AAG along with other chemotherapeutics, providing an opportunity to overcome
228 pressive cancer microenvironment and include chemotherapeutics, radiation, indoleamine 2,3-dioxygenas
231 in synergistic combination with conventional chemotherapeutics, represents an alternative approach to
232 eatment of tumor-bearing mice with different chemotherapeutics resulted in a three- to 10-fold increa
235 ge of cellular interactions of Pt(II) -based chemotherapeutics, robust and efficient methods to track
237 oside levels, and co-treatment with standard chemotherapeutics sensitized cells to mitochondrial memb
238 intervention studies using standard-of-care chemotherapeutics showed the value of this model in dete
239 t in response to UV irradiation or genotoxic chemotherapeutics, SOX9 is actively degraded in various
240 e show that DNA double strand break-inducing chemotherapeutics stimulate CycG2 expression and correla
241 erful platform for the development of cancer chemotherapeutics, stimulated by the Hoffmann-La Roche d
242 nd is differentiated from other DNA-targeted chemotherapeutics such as cisplatin by its potency, cell
244 ingly, these cells are not only resistant to chemotherapeutics such as doxorubicin, but also are stim
245 rse range of substrates includes many common chemotherapeutics such as imatinib, doxorubicin, and mit
251 perature-sensitive liposomal formulations of chemotherapeutics, such as doxorubicin, can achieve loca
254 e-clinical rapid in vivo validation of novel chemotherapeutics targeting early lesions in patients fo
255 rom a drug screen consisting of conventional chemotherapeutics tested on patient-derived cell lines.
257 t some Food and Drug Administration-approved chemotherapeutics that can inhibit the growth of Drosoph
258 late BRCA2-deficient cancer cell response to chemotherapeutics that cause fork degradation.BRCA prote
259 novel nanocarrier for the co-delivery of two chemotherapeutics that have distinctive mechanisms of ac
260 hat can be exploited for design of potential chemotherapeutics that specifically inhibit CatD and rel
261 tes and provide the rationale for developing chemotherapeutics that stabilize the covalent Tdp1-DNA i
264 stic insights could aid development of novel chemotherapeutics that target pathological changes in th
266 eatment for childhood leukemia, but like all chemotherapeutics, their use is limited by inherent or a
269 f chikungunya, supporting the development of chemotherapeutics through drug discovery and design targ
271 concept for a method to enhance delivery of chemotherapeutics to breast cancer cells within the bone
273 e the tendency of topoisomerase II-targeting chemotherapeutics to generate secondary malignancies.
274 rapy or combination therapy with established chemotherapeutics to improve treatment outcomes in CRC p
275 igate the potential clinical use of low dose chemotherapeutics to induce differentiation instead of c
278 practical method for delivering both RNA and chemotherapeutics to tumor cells and expands existing na
279 ive vaccines, more reliable diagnostics, and chemotherapeutics, tuberculosis remains a threat to glob
282 drugs constitute a major class of cytotoxic chemotherapeutics used in the clinic, killing cancer cel
286 form an integrated detoxification unit with chemotherapeutics, we assessed whether these proteins co
287 c bifunctional silyl ether (ABS) prodrugs of chemotherapeutics were synthesized and incorporated with
288 NA damage induction by ionizing radiation or chemotherapeutics, whereas cancer cells typically remain
289 re, therefore, critical for developing novel chemotherapeutics, which are currently limited because o
290 o the resistance of melanoma to DNA-damaging chemotherapeutics, which is one of the major obstacles t
291 sensitivity of cancer cells to DNA-damaging chemotherapeutics, which may induce certain repair genes
292 the effectiveness of existing drugs such as chemotherapeutics, while simultaneously enabling the del
293 obtain resistance, the development of novel chemotherapeutics with a broad activity spectrum, high e
294 r findings is that supplementing traditional chemotherapeutics with anti-inflammatories may reduce tu
295 to improve the delivery and effectiveness of chemotherapeutics with low molecular weights, but it rem
296 ultiple chemotherapeutics or combinations of chemotherapeutics with other treatment modalities like s
297 carboxylated gallium corroles are promising chemotherapeutics with the advantage that they also can
298 pies involving various oncolytic viruses and chemotherapeutics, with the goal of inducing tumor-speci
299 and eradicated, at which point conventional chemotherapeutics would be sufficient to eliminate the r
300 agents as diagnostic probes mirrors that of chemotherapeutics; yet despite an increasing number of P